The Prospective oral mucositis audit: Relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT

Bone Marrow Transplantation

Volumn 43, Issue 2, 2009, Pages 141-147

  McCann, S ^a   Schwenkglenks, M ^b   Bacon, P ^c   Einsele, H ^d   D'Addio, A ^e   Maertens, J ^f   Niederwieser, D ^g   Rabitsch, W ^h   Roosaar, A ⁱ   Ruutu, T ^j   Schouten, H ^k   Stone, R ^l   Vorkurka, S ^m   Quinn, B ⁿ   Blijlevens, N ^o  

^a ST JAMES S HOSPITAL   (Ireland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c AMGEN INC   (United States)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e Institute of Haematology and Medical Oncology 'L and A Seragnoli'   (Italy)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g UNIVERSITY OF LEIPZIG   (Germany)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ KAROLINSKA INSTITUTE   (Sweden)

^j HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^k MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^l NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^m CHARLES UNIVERSITY   (Czech Republic)

ⁿ ST GEORGE S HOSPITAL   (United Kingdom)

^o RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; ANTIBIOTIC AGENT; CARMUSTINE; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; ITRACONAZOLE; MELPHALAN; NYSTATIN; OPIATE; VALACICLOVIR;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG MEGADOSE; DYSPHAGIA; EUROPEAN UNION; FEMALE; FEVER; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NEUTROPHIL; NONHODGKIN LYMPHOMA; OBSERVATIONAL STUDY; PAIN; PRIORITY JOURNAL; PROSPECTIVE STUDY; TOTAL PARENTERAL NUTRITION; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANALGESICS, OPIOID; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CYTARABINE; ETOPOSIDE; FEMALE; HUMANS; LENGTH OF STAY; LYMPHOMA, NON-HODGKIN; MALE; MEDICAL AUDIT; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PROSPECTIVE STUDIES; RISK FACTORS; STEM CELL TRANSPLANTATION; STOMATITIS; TRANSPLANTATION CONDITIONING;

EID: 59549101097     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.299     Document Type: Article

References (31)

1. Blijlevens N, Schwenkglenks M, Bacon P, D'Addio A, Einsele H, Maertens J et al. Prospective oral mucositis audit: Oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy - European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol 2008; 26: 1519-1525.
2. Blijlevens N, Sonis S. Palifermin (recombinant keratinocyte growth factor-1): A pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Ann Oncol 2007; 18: 817-826.
3. Peterman A, Cella D, Glandon G, Dobrez D, Yount S. Mucositis in head and neck cancer: Economic and quality-of-life outcomes. J Natl Cancer Inst Monogr 2001; 29: 45-51.
4. Stiff PJ, Emmanouilides C, Bensinger WI, Gentile T, Blazar B, Shea TC et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol 2006; 24: 5183-5185.
5. Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003; 98: 1531-1539.
6. Fanning SR, Rybicki L, Kalaycio M, Andresen S, Kuczkowski E, Pohlman B et al. Severe mucositis is associated with reduced survival after autologous stem cell transplantation for lymphoid malignancies. Br J Haematol 2006; 135: 374-381.
7. Lark RL, McNeil SA, VanderHyde K, Noorani Z, Uberti J, Chenoweth C. Risk factors for anaerobic bloodstream infections in bone marrow transplant recipients. Clin Infect Dis 2001; 33: 338-343.
8. Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J et al Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001; 19 2201-2205.
9. Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S. Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies. Support Care Cancer 2007; 15: 491-496.
10. Stone R, Potting CM, Clare S, Uhlenhopp M, Davies M, Mank A et al. Management of oral mucositis at European transplantation centres. Eur J Oncol Nurs 2007; 11 (Suppl 1): S3-S9.
11. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. World Health Organization: Geneva, 1979.
12. Quinn B, Stone R, Uhlenhopp M, McCann S, Blijlevens N. Ensuring accurate oral mucositis assessment in the European Group for Blood and Marrow Transplantation Prospective Oral Mucositis Audit. Eur J Oncol Nurs 2007; 11 (Suppl 1): S10-S18.
13. Ruescher TJ, Sodeifi A, Scrivani SJ, Kaban LB, Sonis ST. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 1998; 82: 2275-2281.
14. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351: 2590-2598.
15. Blijlevens NM, Donnelly JP, De Pauw BE. Mucosal barrier injury: Biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: An overview. Bone Marrow Transplant 2000; 25: 1269-1278.
16. Sonis ST. A biological approach to mucositis. J Support Oncol 2004; 2: 21-32; discussion 35-6.
17. Tsuji E, Hiki N, Nomura S, Fukushima R, Kojima J, Ogawa T et al. Simultaneous onset of acute inflammatory response, sepsis-like symptoms and intestinal mucosal injury after cancer chemotherapy. Int J Cancer 2003; 107: 303-308.
18. Logan RM, Stringer AM, Bowen JM, Yeoh AS, Gibson RJ, Sonis ST et al The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: Pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev 2007; 33: 448-460.
19. Warren RS, Starnes Jr HF, Gabrilove JL, Oettgen HF, Brennan MF. The acute metabolic effects of tumor necrosis factor administration in humans. Arch Surg 1987; 122: 1396-1400.
20. Dale DC, Bonilla MA, Davis MW, Nakanishi AM, Hammond WP, Kurtzberg J et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993; 81: 2496-2502.
21. Lieschke GJ, Ramenghi U, O'Connor MP, Sheridan W, Szer J, Morstyn G. Studies of oral neutrophil levels in patients receiving G-CSF after autologous marrow transplantation. Br J Haematol 1992; 82: 589-595.
22. Lockhart PB, Sonis ST. Relationship of oral complications to peripheral blood leukocyte and platelet counts in patients receiving cancer chemotherapy. Oral Surg Oral Med Oral Pathol 1979; 48: 21-28.
23. Woo SB, Sonis ST, Monopoli MM, Sonis AL. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 1993; 72: 1612-1617.
24. Wardley AM, Jayson GC, Swindell R, Morgenstern GR, Chang J, Bloor R et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol 2000; 110: 292-299.
25. Rapoport AP, Miller Watelet LF, Linder T, Eberly S, Raubertas RF, Lipp J et al. Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol 1999; 17: 2446-2453.
26. Kenny SA. Effect of two oral care protocols on the incidence of stomatitis in hematology patients. Cancer Nurs 1990; 13: 345-353.
27. Cheretakis C, Dror Y, Glogauer M. A noninvasive oral rinse assay to monitor engraftment, neutrophil tissue delivery and susceptibility to infection following HSCT in pediatric patients. Bone Marrow Transplant 2005; 36: 227-232.
28. Wright DG, Meierovics AI, Foxley JM. Assessing the delivery of neutrophils to tissues in neutropenia. Blood 1986; 67: 1023-1030.
29. Grazziutti ML, Dong L, Miceli MH, Krishna SG, Kiwan E, Syed N et al Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: Incidence, risk factors and a severity predictive model. Bone Marrow Transplant 2006; 38: 501-506.
30. Kühne A, Sezer O, Heider U, Meineke I, Muhlke S, Niere W et al. Population Pharmacokinetics of Melphalan and Glutathione S-transferase Polymorphisms in Relation to Side Effects. Clin Pharmacol Ther 2008; 83: 749-757.
31. Keefe DM, Schubert MM, Eting LS, Sonis ST, Epstein JB, Roher-Durlocher JE et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007; 109: 820-831.